...
首页> 外文期刊>Medicine. >A case report of a child with sepsis induced multiorgan failure and massive complement consumption treated with a short course of Eculizumab: A case of crosstalk between coagulation and complement?
【24h】

A case report of a child with sepsis induced multiorgan failure and massive complement consumption treated with a short course of Eculizumab: A case of crosstalk between coagulation and complement?

机译:一例短期使用依库丽单抗治疗的败血症诱发多器官衰竭和大量补体摄入量患儿的病例报告:凝血与补体之间串扰的案例?

获取原文

摘要

Rationale: This article describes a child with a life-threatening multiorgan failure with disseminated intravascular coagulation (DIC) and massive complement consumption. To our knowledge this therapeutic approach was for the first time effectively applied in a pediatric patient. Patient concerns: A 14-month-old boy was presented with a severe, rapidly progressing, life-threatening disease because of sudden onset of fever, hemathemesis, hematuria, and bloody diarrhoea alongside fast spreading hematomas and general corporeal edema. Diagnosis: The most plausible diagnosis in our patient is Clostridium difficile sepsis -induced thrombotic microangiopathy alongside with DIC and consumption coagulopathy. The diagnosis was confirmed by positive C difficile bacteria strain in coproculture, clinical, and laboratory tests affirming DIC and global complement activation and consumption. Interventions: The patient was treated with antibiotics (Metronidazole, Vancomycin), plasmapheresis, dialysis, methylprednisolone, mycophenolate mofetil, and Eculizumab . Outcomes: The child is in fair overall condition in a 2 year follow-up with no complications save chronic renal failure. Lessons: In rare cases of sepsis with massive complement consumption, a case-sensitive Eculizumab therapy may be at least considered after the resolution of life-threatening multiorgan failure . The application of this drug can be performed only after sepsis induced disease is put under control. A fast withdrawal of Eculizumab after control of massive complement consumption is recommended to prevent triggering of second sepsis reactivation.
机译:基本原理:本文描述了一个患有致命性多器官衰竭的儿童,其弥散性血管内凝血(DIC)和大量补体消耗。据我们所知,这种治疗方法是第一次有效地应用于儿科患者。病人关注:由于发烧,止血,血尿和血性腹泻的突然发作以及快速扩散的血肿和全身性水肿,给一个14个月大的男孩带来了严重的,迅速发展的,威胁生命的疾病。诊断:在我们的患者中,最合理的诊断是艰难梭菌败血症引起的血栓性微血管病以及DIC和消耗性凝血病。在共培养,临床和实验室测试中确认DIC和整体补体激活和消耗的阳性艰难梭菌属菌株证实了该诊断。干预措施:该患者接受了抗生素(甲硝唑,万古霉素),血浆置换,透析,甲基强的松龙,霉酚酸酯和依库丽单抗治疗。结果:在为期2年的随访中,该患儿总体情况尚可,没有任何并发​​症,但没有慢性肾功能衰竭。经验教训:在罕见的败血症,大量补充补体的情况下,至少在解决威胁生命的多器官衰竭后,才应考虑对病例敏感的依库丽单抗治疗。仅在控制败血症诱发的疾病后才可使用该药物。建议控制大量补体摄入后快速停用依库丽单抗,以防止引发第二次败血症激活。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号